Histogen to Report Third Quarter 2020 Earnings on November 12, 2020
Histogen Inc. (NASDAQ: HSTO) will announce its third-quarter financial results for the period ending September 30, 2020, on November 12, 2020, after market close.
Rhea-AI Summary
Histogen Inc. (NASDAQ: HSTO) will announce its third-quarter financial results for the period ending September 30, 2020, on November 12, 2020, after market close. The company focuses on developing first-in-class restorative therapeutics aimed at enhancing biological functions through its innovative technology platform that utilizes cell conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells. Histogen’s applications include hair growth, dermal rejuvenation, joint cartilage regeneration, and spinal disk repair.
Positive
- Potential first-in-class restorative therapeutics
- Innovative technology platform with broad applications
Negative
- None.
Details
News Market Reaction – HSTO
In the trading session that priced this news, HSTO declined 2.78%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that Histogen’s financial results for the third quarter ended September 30, 2020 will be released after the close of market on Thursday, November 12, 2020.
About Histogen Inc.
Histogen Inc. is a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. Histogen’s innovative technology platform utilizes cell conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells. Histogen’s proprietary, reproducible manufacturing process provides targeted solutions across a broad range of therapeutic indications including hair growth, dermal rejuvenation, joint cartilage regeneration and spinal disk repair. For more information, please visit www.histogen.com.
CONTACT:
Susan A. Knudson
Executive Vice President & CFO
Histogen Inc.
ir@histogen.com